Adverse drug events (ADEs) 
includes both RxNORM and NDF-RT) [22] we are able to map many different vaccines from different manufacturers to the same core ingredient set. Others obtained high quality results when using this same CDM mapping for medications [24] . Using the CDM also helps minimize terminology mapping issues common when using EHRs for medication information [25] . In the OMOP CDM [22] , one code for "adverse effect due to correct medicinal substance properly administered" maps to 75 ICD-9 codes (each with relatively low prevalence). We used this mapping and extracted a population of 16,296 patients with a coded ADE from an appropriately prescribed and administered drug. Because we were interested in vaccines, we extracted all patients who were vaccinated in our medical system (N=70,050). Subsequently, we recorded patients as having a vaccine-related ADE if the ADE occurred within a 3-month window (i.e., 90 days) after the vaccination date. We selected a 3-month window because there is literature suggesting that over 8 weeks time may be necessary to appropriately capture a vaccine-related ADE [26] . If several ADEs occurred within the 3-month time frame (e.g., one 2 days, and another 7 days after vaccination) then both were included in the analysis. This was done because both clinician-coded ADEs could be the result of the vaccination.
Phase One: Mining Vaccine-ADE Associations Across All Vaccinated Patients
The first part of our algorithm (Figure 1) calculates the association between each vaccine and an ADE within 3 months by comparing each individual vaccine (case) to all other vaccines in our dataset (as controls). Controls include all patients who were vaccinated regardless of whether they returned to the hospital for a follow-up visit. Associations are measured using the fisher-exact test with multiplicity correction using Bonferroni's method (R v.3.1.0).
Phase Two: Mining Vaccine-ADE Associations Adjusting for Health-Care Process and Demographic Effects
To adjust for various health-care process effects [8, 9] that may affect whether or not a patient returns to CUMC within 3 months, we decided to use as controls all patients who were vaccinated and were subsequently diagnosed with some other medical condition (not an ADE) within 3 months of the vaccination date. Our cases remained unchanged and consisted of all vaccinated patients with an ADE diagnosis within 3 months. Therefore, in this second phase of the algorithm both cases and controls returned to CUMC within 3 months. For this analysis, we had 65,708 controls and the same 1,231 cases (Figure 1) . We measured the association between each vaccination and an ADE diagnosis using logistic regression. Specifically, each potential confounder (i.e., ethnicity, race, sex, age (at time of vaccination)) was modeled as a covariate in the logistic regression equation with the binary response (outcome) variable indicating the presence or absence of an ADE within 3 months of vaccination and the predictor variable denoting presence or absence of the vaccine of interest (R v.3.1.0). An association is reported as significant if the Bonferroni adjusted p-value is <=0.05. We further illustrate phase two's control selection method in Figure 2. 
Results

Overview of CUMC Dataset
Our dataset contained 472,451 patients with both medication and diagnosis-related information. We found 19 vaccines prescribed at CUMC with at least one patient with a recorded ADE within 3 months after vaccination. In total, 1,231 vaccinated patients were diagnosed with an ADE within 3 months, and We applied our algorithm to all 19 vaccines and measured the association between the vaccine's administration and an ADE within 3 months afterwards. After Bonferroni adjustment, we found 13 vaccines were associated with an ADE at this step. Characteristics of our case patients are shown in Figure 3 (note that the case population did not change between methods). All results from both phases of the algorithm are provided in Table 1 ).
In several instances we found that all patients who returned to CUMC within 3 months had an ADE diagnosis. This includes five vaccines typically given to infants: pertussis/diphtheria/tetanus; hepatitis B surface antigen; tetanus; diphtheria/haemophilus B; Polio 3 types. While interesting, none of these vaccines were significant after adjusting for demographic confounders and multiplicity.
Discussion 4.1 Important Vaccine-ADE Associations
Vaccine-related ADEs can result from a number of different mechanisms important for achieving precision medicine [27] . Our two-phase algorithm was developed specifically for finding vaccines associated with clinician-coded ADEs in EHRs and was agnostic to the mechanism underlying the vaccine-ADE relationship. Interestingly, two types of swine flu vaccines were positively associated with an increased risk of an ADE within 3 months of vaccination after adjustment for confounders (Table 1) , namely the combo H1N1 / H3N2 / B-brisbane influenza (OR=3.207, p<0.001) vaccine and the influenza A-California-7-2009-(H1N1)v-like virus (OR=9.469, p<0.001) vaccine. Importantly, H1N1 originates in swine [28] and all swine flu vaccines in our study were associated with increased risk of ADEs. This fits well with prior literature supporting vaccine-related ADEs resulting from a different swine flu vaccine in the 1970s [26] , which resulted in very serious ADEs including paralysis. Another study, found a similar result for H1N1 vaccination when compared to general influenza vaccination [29] .
Value of Clinician-Coded ADE Associations
Early detection of ADEs is crucial for patient safety. Using our algorithm, we uncovered several vaccines that resulted in ADEs within 3 months for all patients who returned to CUMC within 3 months ( Table 1) . This was true for several vaccines given to infants. Although the results are not significant after covariate modeling (age is one confounder) it is suggestive of a relationship that may warrant further exploration. There are two main types of Hepatitis B vaccinations at CUMC: Hepatitis B (surface antigen) at a concentration of 0.04 mg/ml and Hepatitis B recombinant at a concentration of 0.01-0.02 mg/ml. Vaccination by the higher dose Hepatitis B vaccine resulted in 9 patients with ADEs out of 9 patients with the vaccine who returned to CUMC within 3 months (100% developed an ADE). Contrastingly, vaccination by the lower dose Hepatitis B recombinant vaccine (half to one-quarter the potency) resulted in ADEs among 1 of 1,617 patients seen at CUMC within 3 months after vaccination. Neither hepatitis vaccine was significantly associated with ADEs after adjusting for age, sex, ethnicity, and race. Patients receiving the higher dose Hepatitis B vaccine were less likely to return within 3 months (9/1474, Table 1 ) then those receiving the lower dose (1617/1659, Table 1 ). A likely explanation is that a higher proportion of infants received the lower dose (0.1-0.2 mg/ml) vaccine (94.45% of those vaccinated were <=0 years); whereas, both infants and toddlers received the higher dose (0.4 mg/ml) vaccination (65.94% of those vaccinated were <=0 years; 27.34% were one year olds). Infants have more wellness visits per year; therefore, vaccines given to a higher proportion of infants would be expected to have a higher return rate within 3 months (which we observed). This also demonstrates how the healthcare process can affect results of retrospective analyses using EHRs. Importantly, we adjusted for these types of biases in our algorithm by comparing patients receiving an ADE within 3 months to those who have returned to the hospital ADE-free within 3 months to help adjust for these biases. We also included age as a covariate in our regression model to adjust for age as well.
Limitations and Future Work
A limitation of our work includes our exclusive use of clinician recorded ADEs from EHRs. Some estimates suggest that only one-tenth of ADEs are clinician reported [30] . Therefore, we may be under-estimating the number of ADEs. We used only clinician-reported ADEs because we wanted to ensure that a clinician had validated the ADE as having occurred (i.e., a "true" ADE). Future work includes further exploration of dose-dependency effects for vaccine-related ADEs. Dosage data was only available for some vaccines at this stage. However, we hope to include clinical text and other data types in future to further tease out dosage effects and their relation to ADE risk.
Conclusion
We present an algorithm for discovering vaccines more likely to result in clinician-reported ADEs within 3 months of vaccination when compared to other vaccines. Our method found several interesting associations including two swine flu vaccinations that are positively associated with ADEs within 3 months of vaccination after confounder adjustment.
